CN103463009A - Application of racemosins A in preparation of medicine treating acute renal failure - Google Patents
Application of racemosins A in preparation of medicine treating acute renal failure Download PDFInfo
- Publication number
- CN103463009A CN103463009A CN2013104712015A CN201310471201A CN103463009A CN 103463009 A CN103463009 A CN 103463009A CN 2013104712015 A CN2013104712015 A CN 2013104712015A CN 201310471201 A CN201310471201 A CN 201310471201A CN 103463009 A CN103463009 A CN 103463009A
- Authority
- CN
- China
- Prior art keywords
- racemosins
- renal failure
- acute renal
- preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to new medical application of racemosins A, in particular to the application of the racemosins A in preparation of the medicine treating the acute renal failure. The application of the racemosins A in preparation of the medicine treating the acute renal failure is disclosed for the first time. The matrix type of the racemosins A belongs to a brand new matrix type. The racemosins A has the advantages of being high in inhibitory activity for the acute renal failure and prominent in substantive features, and makes remarkable progress in preventing the acute renal failure.
Description
Technical field
The present invention relates to the new purposes of compound R acemosins A, relate in particular to the application of Racemosins A in preparation treatment acute renal failure medicine.
Background technology
Acute renal failure (Acute Renal Failure, ARF) be the clinical syndrome caused by many reasons, be found in the clinical departments patient, sickness rate is high and often have serious consequences, for in a short time, (a few hours are to a couple of days) siddhi can sharply descend its characteristics, clinical manifestation is acute oliguria (urine amount<400mLPd) or anuria (urine amount<100mLPd), in body, nitrogen matter metabolite is discharged and is produced obstacle, azotemia appears rapidly, water and electrolyte, acid base imbalance, and cause each system corresponding function imbalance of whole body.The principal element that causes acute renal failure is the sharply minimizing of renal blood flow, and the oxidative stress and the cell injury that cause due to the nephridial tissue ischemia, finally causes the deterioration of renal tissue structural damage and function.There is no clinically at present the generally acknowledged effective medicine for the treatment of acute renal failure, only can be by correcting water-electrolyte balance, the symptomatic treatment measures such as correction acidosis improve symptom, and the later stage also needs to maintain the body function by hemodialysis.There is the clinical medicine of obvious curative effects rare improving the kidney perfusion obstacle and alleviate aspect Renal tissues damage.
The compound R acemosins A the present invention relates to is one and within 2013, delivers (Ding-Quan Liu, et al., Racemosins A and B, two novel bisindole alkaloids from the green alga Caulerpa racemosa.Fitoterapia, 91 (2013): 15 – 20.) noval chemical compound, this compound has brand-new framework types, finds that it can weaken beta-amyloyd peptide
25-35(A β
25 – 35) human neuroblastoma cell SH-SY5Y cell injury (the Ding-Quan Liu that causes, et al., Racemosins A and B, two novel bisindole alkaloids from the green alga Caulerpa racemosa.Fitoterapia, 91 (2013): 15 – 20.), the purposes of the Racemosins A the present invention relates in preparation treatment acute renal failure medicine belongs to open first.
Summary of the invention
The object of the invention is to, according in existing Racemosins A research, not finding that it has the present situation of the report of anti-acute renal failure activity, provides the application of Racemosins A in the anti-acute renal failure medicine of preparation.
Research by us is found, anuria when Racemosins A can improve acute renal failure or oliguria symptom, the function of protection kidney.
Described compound R acemosins A, structure is as shown in formula I:
The purposes of the Racemosins A the present invention relates in the anti-acute renal failure medicine of preparation belongs to open first, because framework types belongs to brand-new framework types, and it suppresses active strong for acute renal failure, possess outstanding substantive distinguishing features, obviously there is significant progress for anti-acute renal failure simultaneously.
The specific embodiment
The preparation method of compound R acemosins A involved in the present invention is referring to document (Ding-Quan Liu, et al., Racemosins A and B, two novel bisindole alkaloids from the green alga Caulerpa racemosa.Fitoterapia, 91 (2013): 15 – 20.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound R acemosins A tablet involved in the present invention:
Get 5 and digest compound Racemosins A, add dextrin 195 grams, mix, conventional tabletting is made 1000.
Embodiment 2: the preparation of compound R acemosins A capsule involved in the present invention:
Get 5 and digest compound Racemosins A, add starch 195 grams, mix, encapsulatedly make 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
The therapeutical effect of experimental example 1:Racemosins A to the acute renal failure rat
(1) experimental technique
Adopt intramuscular injection glycerol to cause the Acute Renal Failure Rats animal model.Select 60 of the healthy male SD rats of 180~220g, Nanjing Medical University's Experimental Animal Center is divided into 5 groups at random: sham operated rats (intramuscular injection normal saline); Model group (intramuscular injection glycerol); Racemosins A I group (0.3mg/Kg)); Racemosins A II group (0.6mg/Kg)); Racemosins A III group (1.2mg/Kg)), each organizes rat tail vein injection saline or Racemosins A immediately after the glycerol modeling, after 12 and 24 hours, is administered once again.
(2) observation index
60 rat lasts give to put into metabolic cage collection twenty-four-hour urine after Racemosins A or normal saline, stay latter 6 hours of urine with 4% chloral hydrate intraperitoneal injection of anesthesia, reach the rear bilateral renal blood flow for the treatment of after adopting laser Doppler flowmetry to measure modeling, average as single animal renal blood flow; Get blood and prepare serum, measure blood BUN and Cre; Get kidney, prepare 10% renal cortex homogenate, measure renal cortex homogenate MDA, GSH, NO(all by the operation of test kit description).(3) experimental result
1.Racemosins A can increase acute renal failure Mouse Kidney blood flow
The impact of table 1Racemosins A on acute renal failure Mouse Kidney blood flow
* P<0.05 contrasts with the acute renal failure model group
2.Racemosins A is to the protective effect of acute renal failure Mouse Kidney function tool
The model group rat significantly reduces than rats in sham-operated group twenty-four-hour urine amount, is respectively 4.57 ± 0.74ml and 11.82 ± 2.36ml; Middle and high dosage Racemosins A group twenty-four-hour urine amount is significantly higher than model group (P<0.05), and the urine measurer of three medication therapy groups has dose dependent, is respectively I group 5.48 ± 0.87ml, II group 7.82 ± 1.32ml, III group 9.68 ± 1.50ml.Illustrate that Racemosins A can improve the oliguria symptom of acute renal failure rat.
Acute renal failure rat intravenous injection normal saline is after 24 hours, and serum BUN is 25.53 ± 1.62mmol/L, and Cre is 168.56 ± 13.01umol/L, apparently higher than sham operated rats, illustrates that model group animal renal function injury is serious.Middle and high dosage Racemosins A can improve the renal function (P<0.05) of acute renal failure rat in dose dependent ground.In Table 2.
Each rats in test groups renal function index of table 2 relatively
* P<0.05 contrasts with the acute renal failure model group
Conclusion: anuria when Racemosins A can improve acute renal failure or oliguria symptom, the function of protection kidney, can be used for preparing anti-acute renal failure medicine.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013104712015A CN103463009A (en) | 2013-10-11 | 2013-10-11 | Application of racemosins A in preparation of medicine treating acute renal failure |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013104712015A CN103463009A (en) | 2013-10-11 | 2013-10-11 | Application of racemosins A in preparation of medicine treating acute renal failure |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103463009A true CN103463009A (en) | 2013-12-25 |
Family
ID=49788207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013104712015A Pending CN103463009A (en) | 2013-10-11 | 2013-10-11 | Application of racemosins A in preparation of medicine treating acute renal failure |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103463009A (en) |
-
2013
- 2013-10-11 CN CN2013104712015A patent/CN103463009A/en active Pending
Non-Patent Citations (2)
Title |
---|
DING-QUAN LIU: "Racemosins A and B, two novel bisindole alkaloids from the green alga caulerpa racemosa", 《FITOERAPIA》 * |
谷晓辉: "新型海洋双吲哚类生物碱的研究进展", 《有机化学》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102872115B (en) | Application of Houttuynoid A in preparing medicament for treating acute renal failure | |
CN103599102B (en) | Application of Nitrosporeusines A in drugs for treating acute renal failure | |
CN103599105B (en) | Application of Caesanines D in drugs used for treating acute renal failure | |
CN103463009A (en) | Application of racemosins A in preparation of medicine treating acute renal failure | |
CN103251637A (en) | Application of Polyflavanostilbene A in preparing medicine for treating acute renal failure | |
CN103356605B (en) | Application of Chukrasone B in preparing medicines for treating acute renal failure | |
CN103356646B (en) | The application of Chukrasone A in preparation treatment acute renal failure medicine | |
CN102861095B (en) | Application of Houttuynoid E in medicine for treating acute renal failure | |
CN102861008A (en) | Application of Aphanamixoid A in medicine for treating acute renal failure | |
CN102872094A (en) | Application of Houttuynoid B in medicine for treating acute renal failure | |
CN103655538B (en) | The application of Hippolachnin A in treatment acute renal failure medicine | |
CN102872140B (en) | Application of Houttuynoid C in drug for treating acute renal failure | |
CN103520172B (en) | The application of Kadcoccitones A in preparation treatment acute renal failure medicine | |
CN103446119B (en) | Application of Fluevirosines A in preparation of acute renal failure treating drug | |
CN103127151A (en) | Application of Gypensapogenin A in medicines treating acute renal failure | |
CN103462996A (en) | Application of Neonectrolide A in preparing medicament for treating acute renal failure | |
CN105456238A (en) | Application of Norsampsone A in preparation of drug for treating acute renal failure | |
CN105287529A (en) | Application of Lycojaponicumins A in preparation of acute renal failure treating medicine | |
CN105078954A (en) | Medicine for treating acute renal failure and application thereof | |
CN105287481A (en) | Application of Concrescenin A in preparation of medicine for treating acute renal failure | |
CN103356543A (en) | Application of Sarcaboside A in preparation of drug for treating acute renal failure | |
CN105497040A (en) | Application of Astataricusol A in preparing of medicine for treating acute renal failure | |
CN103356527A (en) | Application of Sarcaboside B in medicine used for treating acute renal failure | |
CN103340877A (en) | Application of Aspeverin in preparation of medicine for treating acute renal failure | |
CN106389420A (en) | Applications of Ternatusine A in preparing medicines for treating acute renal failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131225 |